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and T.E. Starzl 
I N both rats and dogs, the immunosuppressive drugs 
cyclosporine (CyA) and FK 506 augment liver regen-
eration and possess other hepatotrophic qualities. J-4 In 
contrast, rapamycin (RPM), a powerful immunosuppres-
sant that is chemically related to FK 506 but targeted to a 
different stage of T-cell activation,5,6 was recently shown 
to have antiproliferative properties, including inhibition of 
regeneration of the livers, as well as of the intestine and 
kidney.7,8 However, there is a paucity of information 
about the influence of other immunosuppressive drugs on 
growth and regeneration, Using in vivo (partial hepatec-
tomy and portacaval shunt) and in vitro (tissue culture) 
experimental models described elsewhere,2-4,8-10 we have 
investigated the effect on hepatocyte proliferation of meth-
ylprednisolone (MP), mycophenolic acid (MPA), mizorib-
ine (MZ), azathioprine (AZA), and prostaglandin EJ 
(POE J ), 
MATERIALS AND METHODS 
In Vitro Study 
Hepatocytes in Primary Culture. The livers were removed 
from 7-week-old male rats (Fischer 344 purchased from Hilltop 
Lab Animals Inc, Scottdale, Pal weighing 180 to 200 g. Hepato-
cytes were isolated by a modification of the in situ two-step 
collagenase perfusion technique of Seglen and Jirtle et al. 11.12 The 
hepatocytes were dispersed and washed twice with cold Ca2+ free 
perfusion buffer and resuspended in basal medium (MEM) sup-
plemented with pyruvate (1 mmollL), proline (0,26 mmollL), 
insulin (10-7 mollLJ and 5% fetal calf serum. Viability was 
determined by Trypan blue exclusion, and only preparations 
having >90% viability at the outset were used. Cell number was 
determined with a hemocytometer. The cells were plated at a cell 
density of 6,5 x 104 per well in Coming 35 mm tissue culture 
dishes (Coming, NY) containing 1,5 mL medium and maintained 
at 37°C in a 5% CO2 atmosphere. After a 3-hour attachment 
period, the medium was aspirated and 1.5 mL MEM containing 
epidermal growth factor (EOF) and insulin at concentrations of 10 
ng/mL and 10-7 mollL, respectively, were added. The substances 
were dissolved in DMSO (MPA), saline (MZ), or ethanol (POE I , 
MP, AZA) and added in the appropriate concentrations. The 
amount of alcohol or DMSO added to the medium was never more 
than 2 JLL/mL, which does not affect hepatocyte proliferation. 
In Vitro f H] Thymidine Incorporation.· To determine in vitro 
DNA synthesis, 3 jLCWHlthymidine (Dupont New England Nu-
clear Research Products, Boston, Mass) was added to each well 
and maintained for 24-48 hours of the culture period. When the 
cells were harvested, DNA content was determined by the mi-
crofluorometric method of Setara and Morley,13 and DNA syn-
thesis was measured by the method of Michelopoulos et al. 14 
Table 1, Regimens 
Dose Used 
Group Drugs (mglkg/dose) Route Vehicle 
1 (n = 5) 1M Saline 
2 (n = 10) MP 1M Saline 
3 (n = 5) 1M Saline 
4 (n = 10) MZ 20 1M Saline 
5 (n = 5) PO 0.5% CMC; 0.4% Tween 
0.9 alcohol in saline 
6(n = 10) MPA 15 PO 0.5% CMC; 0.4% Tween 
0.9% alcohol in saline 
7 (n = 5) 1M 1 % CMC in saline 
8(n = 10) AZA 6 1M 1 % CMC in saline 
9 (n = 5) 1M 10% ethanol in saline 
10 (n = 10) PGE, 0.2 1M 10% ethanol in saline 
MP and MZ were dissolved in saline; MPA was dissolved in 0.5% carbossil-
methil-cellulose (CMC), 0.4% Tween, and 0.9% alcohol in saline; AZA was mixed 
wnh olive oil or dissolved w~h 1% CMC in saline; PGE, was dissolved in alcohol 
and diluted 10 times with saline. 
In Vivo Study 
70% Partial Hepatectomy: Rat Model. Rats similar to those 
used in the in vitro experiments were assigned to groups and 
treated for 4 days as controls or with drugs (Table I). On the 4th 
day, between 0900 and 1030 hours, the rats received a standard 
70% hepatectomy under light ether anesthesia. Food and drink 
were allowed immediately. Parenteral fluid and electrolyte sup-
port were not required. 
Twenty-four hours after the hepatectomies, 185 x 10-4 Bq [3Hl 
thymidine was administered to all rats by intraperitoneal injection. 
The rats were killed 2 hours later by guillotine. Extraction and 
purification of hepatic DNA were accomplished by the method of 
Ove et al l5 and DNA content was measured with calf thymus 
DNA (Sigma, St Louis, Mo) as the standard. 16 Specimens from 
each liver were prepared for histological examination with hema-
toxylin-eosin and the proportion of labeled hepatocytes was 
counted. 
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Fig 1. Effect of different doses of MP, PGE" MZ, and MPA on DNA synthesis in hepatocy1es cultured in the presence of EGF (10 ng/mL). 
In some experiments, MP was tested in the absence of insulin, and PGE, in the absence of EGF. N = 9 for all data points, which represent 
three experiments with triplicate determinations. Data expressed as mean ± SO. *P < .05; **P < .01. 
Portacaval Shunt: Dog Model. Conditioned female beagle dogs 
underwent a functional end-to-side portacaval shunt (PCS) as 
previously described. 4•9 . 'o POE, was dissolved daily in vehicle 
solution (5 mmollL ammonium acetate. 5 mg/L bovine serum 
albumin in saline) and infused for 4 days into the left branch of the 
portal vein. 
At day 4, 0.2 mCilkg of intravenous (IV) [3Hl thymidine was 
given with a specific activity of 80-90 Cilmmol. Two hours later, 
while the dogs were under sodium pentobarbital anesthesia, 
specimens were taken from left and right lobes of the liver and 
fixed in 10% normal buffered formalin. The dogs were killed with 
an IV bolus of potassium chloride. 
Hepatocyte size and organelle structure were quantitated, and 
proliferation was estimated by nuclear thymidine incorporation 
(classical autoradiography). These parameters were compared in 
the left (treated) vs the right (untreated) lobes. 
Statistical Analysis. Data were reported as mean ± SD. Stu-
dent's one-tailed t test was used to determine the significance of 
differences. A P value <.05 was considered significant. 
RESULTS 
In Vitro Hepatocy1e Viability 
MP A and MZ that were added after a 3-hour attachment 
period did not alter the DNA or AL T concentration in the 
medium after 48 hours of incubation (data not shown). In 
contrast, AZA killed the hepatocytes, making continuation 
of the experiment impossible. 
Figure 1 shows the effect in vitro on hepatocyte prolif-
eration maintained for 48 hours in the presence of MP, 
MPA, MZ, and POE •. MZ and MPA inhibited DNA 
synthesis, whereas MP caused a near doubling of thymine 
incorporation. POE. feebly stimulated hepatocyte prolif-
eration at the higher concentration. This effect was over-
lapped by EOF stimulation. 
In Vivo Results 
Table 2 reports the results obtained in the experiment in 
vivo using the 70% partial hepatectomy rat model. 
After partial hepatectomy, the different vehicle solu-
tions showed considerable variability in liver regeneration. 
It suggested the need for concurrent controls for each test 
group. 
The only drug that significantly augmented regeneration 
relative to the controls was MP. The only drug that 
significantly inhibited regeneration was MZ (Table 2). The 
MZ inhibition was profound, reducing DNA synthesis and 
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Table 2. Effects of MP, MZ, MPA, AZA, and PGE, on Liver Regeneration in 70% Partial Hepatectomy Rat Model 
Group 
1 (n = 5) 
2 (n = 10) 
3 (n = 5) 
4 (n = 10) 
5 (n = 5) 
6 (n = 10) 
7 (n = 5) 
8 (n = 10) 
9 (n = 5) 
10 (n = 10) 
Substances 
Vehicle 
MP 
Vehicle 
MZ 
Vehicle 
MPA 
Vehicle 
AZA 
Vehicle 
PGE, 
• P < .05 vs their own control group. 
Dose Used 
(mglkg/dose) 
20 
15 
6 
0.2 
the labeled nuclei rate. MPA, AZA, and PGE I had no 
effect on regeneration in the whole animal (Table 2). 
In contrast, PGE I was found profoundly active when 
infused continuously for 4 days into the left branch of the 
portal vein in the pes dog model (Table 3). 
CONSIDERATIONS 
AZA, MPA, and MZ are cytotoxic agents. They act by 
selectively inhibiting the synthesis of purine nucleotides 
(adenine for AZA and guanine for MPA and MZ), thereby 
reducing DNA synthesis of a variety of immunologic and 
other specialized cells, including hepatocytes. 
In accord with this, our in vitro results show both an 
inhibitory effect of MP A and MZ and a toxic one of AZA. 
In in vivo experiments, only MZ confirmed the inhibition 
found in vitro, whereas AZA and MPA at the doses used 
did not affect liver regeneration in rats after 70% partial 
hepatectomy. 
The inhibition of hepatocyte proliferation by cytotoxic 
drugs is consistent with previous reports about AZA.17 A 
seemingly obvious explanation could be that AZA, MP A, 
and MZ selectively inhibit synthesis of purine nucleotides, 
which are required for DNA synthesis. 
MP augmented liver regeneration in intact animals, and 
caused a striking increase in hepatocyte proliferation in 
culture. The absence of insulin in the medium drastically 
reduces MP stimulation to a level that is no longer signif-
icant (Figure 1). 
MP is known to inhibit the synthesis and expression of 
DNA Percent of 
Route (cpm/mg x 10-3 ) Labeled Nuclei 
1M 91 ± 8 18 ± 3 
1M 153±11· 39 ± 4-
1M 96 ± 9 18 ± 2 
1M 17 ± 4· 6 ± 2-
PO 66 ± 5 17 ± 3 
PO 63 ± 6 16 ± 4 
1M 59 ± 4 16 ± 3 
1M 56 ± 5 15 ± 3 
1M 88 ± 7 17 ± 2 
1M 96 ± 10 18 ± 3 
mUltiple cytokines, including IL-l, IL-2, and migration 
inhibitor factor. ls •l ,) Although IL-J and IL-2 are thought 
from reported in vitro experiments to be growth suppres-
sors,20 this could not be demonstrated by our laboratory-
sensitive in vivo test system, in which the recombinant 
cytokines in question were infused directly into the tied off 
portal vein of the Eck fistula liver. 21 Thus, the proliferative 
response to MP reported herein both in vivo and in vitro 
cannot be explained with what is currently known about 
steroid actions. 
PGE I has been successfully used in the therapy of 
posttransplant patients, as well as in the therapy of fulmi-
nant hepatic failure (FHF).22-24 The administration of this 
drug after transplantation may reduce immunorejec-
tion22 ,25 and drastically reverses primary graft nonfunction 
after orthotopic liver transplantation. 23 
We demonstrated that PGE1 has hepatotrophic quali-
ties, as is well known for other PGS.26-28 It stimulated 
hepatocyte proliferation in both in vitro and in vivo mod-
els. However, a continuous and topic infusion of PGE1 
seems necessary to stimulate liver regeneration. In fact, 
we were not able to obtain any proliferation in rats treated 
with only one daily if\iection for 4 days. Instead, when the 
drug was injected continuously in one lobe of the liver, we 
noted a stimulation just of the infused lobe. It could mean 
that after the PGE I passes through the liver it is much too 
diluted to stimulate the noninfused lobe or that it is 
promptly degradated as soon as it arrives at the lung.29 
It is not possible to explain the growth effects of PGE1 
by the well-known properties of this drug. Recently, a 
Table 3. Hepatocyte Size and Autoradiographic Labeling After Continuous Infusion of Different Doses of PGE, Into the Left Portal 
Vein Branch of Dogs With Eck's Fistula 
No. of Labeled Hepatocytes per 1,000 
Dose 
Hepatocytes Cell Size (U) 
Group N (l'9/d) Left lobe Right lobe Left lobe Right lobe 
1 2 4.8 12.5 ± 0.5· 5.1 ± 0.7 0.158 ± 0.01· 0.087 ± 0.007 
2 2 0.48 10 ± 0.3- 3.9 ± 0.3 0.161 ± 0.005· 0.100 ± 0.005 
3 2 0.24 6 ± 0.2· 3.8 ± 0.1 0.131 ± 0.004· 0.095 ± 0.009 
4 2 0.048 5.1 ± 0.3 4.6 ± 0.4 0.104 ± 0.002 0.099 ± 0.004 
• P < .05. left lobe vs right lobe. 
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linkage has been proposed between TGFa and PG.28 It 
seems that TGFa may induce hepatocyte proliferation in 
vitro by regUlating the metabolism of arachidonic acid and 
the formation of prostaglandins. However, it is unlikely 
that the beneficial effect of PGE1 in the therapy of FHF is 
due to its growth qualities; in fact, as we described 
elsewhere30 it is not possible to reverse FHF by adminis-
tration of liver growth factors. A more likely explanation 
for the therapeutic action of PGE1 could be the protection 
of the endothelial cells' integrity and an improvement of 
liver blood flOW?t.32 
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